Although ultra-rare and novel heterozygous germline variants in RPA1 were significantly enriched in pediatric cancers, it is difficult to ascertain pathogenicity and clinical relevance without functional follow-up, which falls beyond the scope of this study. The gene discussed is RPA1; the disease is cancer.